Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2002 3
2003 2
2004 2
2005 2
2006 1
2007 4
2008 2
2009 4
2010 1
2011 3
2012 7
2013 5
2014 14
2015 8
2016 6
2017 6
2018 4
2019 7
2020 8
2021 5
2022 6
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Results by year

Filters applied: . Clear all
Page 1
Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
Oda Y, Kumagai Y, Kanai M, Iwama Y, Okura I, Minamida T, Yagi Y, Kurosawa T, Greener B, Zhang Y, Walson JL. Oda Y, et al. Among authors: kumagai y. Lancet Infect Dis. 2024 Apr;24(4):351-360. doi: 10.1016/S1473-3099(23)00650-3. Epub 2023 Dec 20. Lancet Infect Dis. 2024. PMID: 38141632 Clinical Trial.
Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial.
Wada T, Hibino M, Aono H, Kyoda S, Iwadate Y, Shishido E, Ikeda K, Kinoshita N, Matsuda Y, Otani S, Kameda R, Matoba K, Nonaka M, Maeda M, Kumagai Y, Ako J, Shichiri M, Naoki K, Katagiri M, Takaso M, Iwamura M, Katayama K, Miyatsuka T, Orihashi Y, Yamaoka K; CORVETTE-01 Study Group. Wada T, et al. Among authors: kumagai y. Front Med (Lausanne). 2023 May 22;10:1139046. doi: 10.3389/fmed.2023.1139046. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37283627 Free PMC article.
Effects of Low-Dose Colchicine on Serum High-Sensitivity C-Reactive Protein Level in Coronary Artery Disease Patients with Type 2 Diabetes Mellitus and Enhanced Inflammatory Response Protocol for a Randomized, Double-Blind, Placebo-Controlled, Phase 2, Dose-Finding Study.
Miwa Y, Mutoh A, Morimoto T, Ikehara Y, Yasu T, Koba S, Ako J, Higashi Y, Kajikawa M, Uehara H, Ishikawa K, Sakuma I, Tomiyama H, Node K, Kumagai Y, Ueda S. Miwa Y, et al. Among authors: kumagai y. Biomed Hub. 2022 Dec 5;7(3):156-164. doi: 10.1159/000527411. eCollection 2022 Sep-Dec. Biomed Hub. 2022. PMID: 36643381 Free PMC article.
Phase 1 Clinical Trial of PPMX-T003, a Novel Human Monoclonal Antibody Specific for Transferrin Receptor 1, to Evaluate Its Safety, Pharmacokinetics, and Pharmacodynamics.
Ogama Y, Kumagai Y, Komatsu N, Araki M, Masubuchi N, Akiyoshi H, Matsuura T, Kirisako H, Kyoya A, Nomura F, Ohira Y, Yokokawa T, Yamamoto Y. Ogama Y, et al. Among authors: kumagai y. Clin Pharmacol Drug Dev. 2023 Jun;12(6):579-587. doi: 10.1002/cpdd.1216. Epub 2022 Dec 30. Clin Pharmacol Drug Dev. 2023. PMID: 36583544 Clinical Trial.
Appraisal of ICH E14/S7B Q&As adopted in February 2022 using thorough QT/QTc study data for α4-integrin antagonist carotegrast methyl in Japanese healthy subjects.
Kambayashi R, Goto A, Izumi-Nakaseko H, Oikawa I, Ikeda N, Matsuda K, Takei Y, Matsumoto A, Kumagai Y, Sugiyama A. Kambayashi R, et al. Among authors: kumagai y. J Pharmacol Sci. 2022 Nov;150(3):191-199. doi: 10.1016/j.jphs.2022.08.007. Epub 2022 Sep 2. J Pharmacol Sci. 2022. PMID: 36184124 Free article. Clinical Trial.
93 results